Dr Emily Sammons
Contact information
Emily Sammons
BSc, MBChB, MSc
MRC PHRU Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit of the University of Oxford. She has particular research interests in diabetic eye disease and age-related macular degeneration. Alongside this she works on two large randomised controlled trials: ASCEND and REVEAL. ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes. REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease. Emily has background experience of working in General Medicine and a MSc in Public Health.
Recent publications
-
ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy
Journal article
SAMMONS E. et al, (2023), Ophthalmology
-
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
Journal article
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
-
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial
Journal article
Judge P. et al, (2023), Lancet Diabetes and Endocrinology
-
Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the UK and US
Journal article
MIHAYLOVA B. et al, (2023), Journal of the American Heart Association
-
ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
Journal article
SAMMONS E. et al, (2023), Contemporary Clinical Trials Communications